Bevacizumab, one of the agents for recognizing and blocking vascular endothelial growth factor A (VEGF-A), has been a promising agent in a combination regimen in improving the overall survival and progression-free survival of breast cancer, non-small-cell lung cancer, renal cell carcinoma, and other solid malignancies [14], [15]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.